ReviewImmunity, inflammation and disease2026
Knee Osteoarthritis Therapy Targeting NLRP3 Inflammasome: Progress From Mechanism to Application.
Review in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Knee Osteoarthritis Therapy Targeting NLRP3 Inflammasome: Progress From Mechanism to Application.Immunity, inflammation and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis paper briefly reviews the structure, function, and activation mechanism of the NLRP3 inflammasome and its molecular role in the pathogenesis of knee osteoarthritis (KOA), and explores the potential value of traditional Chinese medicine (TCM) in treating KOA by modulating NLRP3 inflammasome activity. The review covers evidence from mechanistic studies, in vitro experiments, in vivo models, and currently available clinical-related findings.
methodsTo investigate the role of the NLRP3 inflammasome in KOA, a comprehensive literature search was conducted across multiple databases, including PubMed, MEDLINE, Web of Science, Scopus, and various Chinese biomedical repositories (CNKI, CBM, VIP, COJ). Emphasis was placed on studies published in the past 5 years concerning TCM-based interventions targeting NLRP3 in KOA models, facilitating comparative analysis and synthesis of recent evidence.
resultsNLRP3 inflammasome has been implicated in multiple pathological processes of KOA, including cartilage degradation, inflammation of the synovium, programmed cell death (pyroptosis), and the activation of osteoclasts. Interventions using TCM-such as herbal monomers, multi-compound formulas, external preparations, and acupuncture-can mitigate these pathological events by modulating NLRP3 activity.
conclusionThe NLRP3 inflammasome is a critical mediator in KOA pathophysiology, influencing inflammation, cartilage deterioration, pyroptosis, and bone metabolism. Strategies derived from TCM that target this inflammasome may offer promising avenues for developing precise and effective treatments for KOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.